Equities

Vytrus Biotech SA

Vytrus Biotech SA

Actions
  • Price (EUR)--
  • Today's Change--
  • Shares traded0.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Vytrus Biotech SA, formerly Phyture Biotech SL, is Spain-based company principally engaged in the biotechnology industry. The Company develops high added value natural active ingredients on an industrial scale and provides ingredients and recombinant proteins for its use in the cosmetics and pharmaceutical sectors. The Company’s technology is based on using plant cell cultures to produce bioactive molecules. The Company obtains plant cells, known as Plant Stem Cell technology, which is applicable for cosmetics. Vytrus Biotech specifically target dermo-cosmetics as well as veterinary medicine, functional food and other pharmaceuticals, generating savings of more than 99% in natural resources.

  • Revenue in EUR (TTM)3.74m
  • Net income in EUR544.95k
  • Incorporated2009
  • Employees36.00
  • Location
    Vytrus Biotech SASant Gaieta 121, 2ndTERRASSA 08221SpainESP
  • Phone+34 931278106
  • Websitehttp://www.vytrus.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.